Indiana University and Eli Lilly and Company have signed a five-year agreement that will provide up to $40 million to expand access to clinical trials and innovative treatments for patients across the state.

The partnership aims to advance research and care in Alzheimer’s disease, diabetes, cancer, and emerging cell and gene therapies while strengthening Indiana’s life sciences workforce.

According to the announcement, the collaboration builds on decades of work between the two institutions and will create what leaders describe as a “best-in-class system for clinical trial innovation.” The effort combines IU’s research and clinical strengths with Lilly’s biopharmaceutical expertise to accelerate patient enrollment, improve trial design and broaden access to investigational medicines.

“I

See Full Page